Abstract
Alzheimers disease (AD), the leading cause of senile dementia, has become a considerable social and economical problem. Current AD therapeutics provide mainly symptomatic short-term benefit, rather than targeting disease mechanisms. The hallmarks for AD are ß-amyloid plaques, neurofibrillary tangles, and regionalized neuronal loss. Additional neuropathological features have been described that may provide some clues to the mechanism by which neurons die in AD. Specifically, the aberrant expression of cell cycle proteins and the presence of de novo-replicated DNA in neurons have been described both in AD brain and in culture models of the disease. The unscheduled cell cycle events are deleterious to neurons, which undergo death rather than complete the cell cycle. Although our understanding of the neuronal cell cycle is not complete, experimental evidence suggests that compounds able of arresting the aberrant cell cycle will yield neuroprotection. This review focuses on drug development centered on the cell cycle hypothesis of AD.
Keywords: Alzheimer's disease, β-amyloid, apoptosis, cell cycle, DNA replication, cyclin-dependent kinases, DNA polymerase-β, neuroprotection
Current Medicinal Chemistry
Title: The Cell Cycle Molecules Behind Neurodegeneration in Alzheimers Disease: Perspectives for Drug Development
Volume: 15 Issue: 24
Author(s): A. Copani, S. Guccione, L. Giurato, F. Caraci, M. Calafiore, M. A. Sortino and F. Nicoletti
Affiliation:
Keywords: Alzheimer's disease, β-amyloid, apoptosis, cell cycle, DNA replication, cyclin-dependent kinases, DNA polymerase-β, neuroprotection
Abstract: Alzheimers disease (AD), the leading cause of senile dementia, has become a considerable social and economical problem. Current AD therapeutics provide mainly symptomatic short-term benefit, rather than targeting disease mechanisms. The hallmarks for AD are ß-amyloid plaques, neurofibrillary tangles, and regionalized neuronal loss. Additional neuropathological features have been described that may provide some clues to the mechanism by which neurons die in AD. Specifically, the aberrant expression of cell cycle proteins and the presence of de novo-replicated DNA in neurons have been described both in AD brain and in culture models of the disease. The unscheduled cell cycle events are deleterious to neurons, which undergo death rather than complete the cell cycle. Although our understanding of the neuronal cell cycle is not complete, experimental evidence suggests that compounds able of arresting the aberrant cell cycle will yield neuroprotection. This review focuses on drug development centered on the cell cycle hypothesis of AD.
Export Options
About this article
Cite this article as:
Copani A., Guccione S., Giurato L., Caraci F., Calafiore M., Sortino A. M. and Nicoletti F., The Cell Cycle Molecules Behind Neurodegeneration in Alzheimers Disease: Perspectives for Drug Development, Current Medicinal Chemistry 2008; 15(24) . https://dx.doi.org/10.2174/092986708785909030
DOI https://dx.doi.org/10.2174/092986708785909030 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Insulin-Degrading Enzyme: A Link Between Alzheimer’s and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets An Aβ Sequestration Approach Using Non-Antibody Aβ Binding Agents
Current Alzheimer Research Fyn Kinase in Brain Diseases and Cancer: The Search for Inhibitors
Current Medicinal Chemistry Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Acetylcholinesterase Inhibitors as a Starting Point Towards Improved Alzheimers Disease Therapeutics
Current Pharmaceutical Design Compensating, Controlling, Resigning and Accepting-Older Persons Perception of Physical Decline
Current Aging Science Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry The Multifunctional Mesencephalic Locomotor Region
Current Pharmaceutical Design Editorial [Hot topic: A Multi-Targeted Approach for a Complex Multifaceted Disease (Guest Editors: D.W. Shineman and H.M. Fillit)]
Current Alzheimer Research Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder
CNS & Neurological Disorders - Drug Targets Current State of Development of Genome Analysis in Livestock
Current Genomics A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer's Disease
Current Alzheimer Research Subject Index To Volume 1
Recent Patents on CNS Drug Discovery (Discontinued) Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Pathophysiology of Neurodegeneration in Familial Amyotrophic Lateral Sclerosis
Current Molecular Medicine Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors
Current Pharmaceutical Design Kleptomania: Differential Diagnosis and Treatment Modalities
Current Psychiatry Reviews Diversity of Senile Plaques in Alzheimers Disease as Revealed by a New Monoclonal Antibody that Recognizes an Internal Sequence of the Aβ Peptide
Current Alzheimer Research Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases
Mini-Reviews in Medicinal Chemistry